Current stock page

Financial Data

NBIX Financial Data

Revenue · Earnings · Margins · Balance Sheet · Cash Flow

HealthcareBiotechnologyScore data as of Nov 13, 2026

NBIXNeurocrine Biosciences, Inc.

Healthcare / Biotechnology

Leader

Strong Relative Position

BullishEdge 9/10
$167.40−$2.00 (−1.18%)

Latest quote

  • Momentum
    70
  • Value
    77
  • Quality
    79
  • Risk resilience
    69
  • Sentiment
    —
algovestiq.comScore data as of Nov 13, 2026

Financial Data Overview

Detailed revenue, earnings, margins, balance sheet, cash flow, valuation metrics, technical indicators, and risk measures for deeper research.

Quarterly periods
8
Fundamental metrics
10
Technical indicators
12
Risk measures
6

Quarterly Financial Statements

Updated Nov 16, 2026.

Income statement
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Revenue$1.12B$959M$814.5M$805.5M$794.9M$687.5M$572.6M$627.7M
Gross Profit$1.1B$935.8M$800.7M$787.9M$780.9M$676.2M$563.4M$618.4M
Operating Income$331.3M$153M$186M$210.9M$239M$145.6M$23.6M$142M
Net Income$206.5M$144.4M$197.9M$153.7M$209.5M$107.5M$7.9M$103.1M
EPS$2.03$1.43$1.97$1.54$2.11$1.09$0.08$1.03
Cash flow statement
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Operating Cash Flow$395.2M$136.4M$145.8M$388.4M$227.5M$102M$64.8M$242.5M
Capital Expenditure-$11.6M-$7.8M-$9.1M$2.4M-$13.2M-$12.5M-$10.7M-$7.3M
Free Cash Flow$383.6M$128.6M$136.7M$390.8M$214.3M$89.5M$54.1M$235.2M
Net Cash Provided By Operating Activities$395.2M$136.4M$145.8M$388.4M$227.5M$102M$64.8M$242.5M
Balance sheet
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Total Assets$5.63B$5.36B$4.91B$4.63B$4.27B$3.89B$3.69B$3.72B
Total Debt$392.3M$401.8M$406.2M$415.3M$428.4M$439.1M$447.5M$455.1M
Cash And Cash Equivalents$641.5M$332.4M$266.5M$713M$340.2M$264M$194.1M$233M
Total Liabilities$1.75B$1.67B$1.5B$1.38B$1.26B$1.2B$1.15B$1.13B
Total Stockholders Equity$3.88B$3.69B$3.41B$3.25B$3B$2.69B$2.54B$2.59B
Key financial metrics
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
P/E ratio23.9227.420.8929.4435.339.6636.7935.82
P/B ratio4.335.234.14.335.035.134.444.72
P/S ratio4.59———————
Debt To Equity0.10.110.120.130.140.160.180.18
Free Cash Flow Yield6.19%4.50%5.95%5.31%3.93%3.83%4.38%4.56%
Financial ratios
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
P/E ratio23.9227.420.8929.4435.339.6636.7935.82
P/B ratio4.335.234.14.335.035.134.444.72
P/S ratio4.59———————
Return On Equity18.11%19.10%19.62%14.71%14.25%12.93%12.06%13.18%
Debt To Equity0.10.110.120.130.140.160.180.18

Current Stock Metrics

Current fundamental, technical, and risk readings in one place.

Fundamental metrics
MetricValue
Pe24.02x
Pb4.38x
Revenue Growth Yoy41.24%
EPS Growth Yoy-3.79%
Gross Margin97.81%
Operating Margin23.81%
ROE19.74%
ROIC14.30%
Debt To Equity0.1
FCF Yield6.14%

As of Nov 13, 2026

Technical indicators
MetricValue
Close$167.40
Volume1.38M
RSI (14)64.45
MACD6.99
MACD signal5
MACD histogram1.99
ADX (14)33.62
SMA (50)$148.58
SMA (200)$148.88
ATR (14)$5.51
Historical volatility (annualized)54.98%
Volume (20-day average)1.44M

As of Nov 13, 2026

Risk measures
MetricValue
Resilience score69/100
Beta0.7
Annual volatility35.22%
Max Drawdown-27.15%
Sharpe Ratio0.49
VaR (95%, 1-day)-3.40%

As of Nov 13, 2026

Detailed Metrics

Additional measures remain available here while the decision pages stay focused.

Additional fundamental metrics

No additional fundamental metrics are available.

Additional technical indicators

No additional technical indicators are available.

Additional risk measures

No additional risk measures are available.

NBIX Financial Data FAQ

What is Neurocrine Biosciences, Inc.'s revenue?

Neurocrine Biosciences, Inc.'s revenue is one of the core financial data points for NBIX. Use it with revenue growth, margins, and EPS to understand whether sales are translating into earnings power.

Is Neurocrine Biosciences, Inc.'s revenue growing?

Revenue growth shows whether Neurocrine Biosciences, Inc. is expanding from prior periods. Compare growth with margins and free cash flow because faster sales growth is more valuable when profitability holds up.

What is NBIX's EPS?

NBIX's EPS, or earnings per share, helps connect net income to each share. EPS should be compared with EPS growth, P/E ratio, and analyst expectations.

What is Neurocrine Biosciences, Inc.'s net income?

Neurocrine Biosciences, Inc.'s net income shows profit after costs, taxes, and other expenses. It should be read with revenue, operating margin, EPS, and free cash flow.

How much free cash flow does Neurocrine Biosciences, Inc. generate?

Free cash flow shows how much cash Neurocrine Biosciences, Inc. generates after capital spending. It is useful for judging reinvestment capacity, buybacks, debt reduction, and valuation support.

How much cash and debt does Neurocrine Biosciences, Inc. have?

Cash and debt help frame NBIX's balance-sheet flexibility. Compare liquidity and leverage with free cash flow and profitability before judging financial strength.